Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Epidemiology

Background:

• The International Prognostic Index (IPI) is a standard tool for risk stratification in diffuse large B-cell lymphoma (DLBCL).
• A significant number of patients with low-risk DLBCL, as defined by IPI, still experience disease progression or mortality.
• There is a need for refined prognostic factors to better identify high-risk individuals within the low-risk DLBCL group.

Purpose of the Study:

• To identify additional pretreatment clinical factors that improve risk stratification for patients with low-risk diffuse large B-cell lymphoma (DLBCL).
• To refine prognostic models beyond the International Prognostic Index (IPI) for selected DLBCL patient cohorts.

Main Methods:

• Analysis of mature, population-based data from the Danish Lymphoma Group.
• Inclusion of 177 patients with DLBCL and favorable IPI scores treated with curative intent.
• Multivariate analysis to identify independent prognostic factors for treatment outcomes.

Main Results:

• Stage II disease and age over 50 years were independently associated with a poor outcome in low-risk DLBCL patients.
• Patients without these adverse factors demonstrated excellent long-term survival (90% at 5 years, 80% at 15 years).
• Patients with both adverse factors had significantly poorer survival rates (70% at 5 years, 29% at 15 years).

Conclusions:

• The International Prognostic Index (IPI) can be enhanced for risk stratification in diffuse large B-cell lymphoma (DLBCL).
• Incorporating Stage II and age >50 into risk assessment can improve prognostic accuracy for low-risk DLBCL patients.
• Simple clinical pretreatment factors offer valuable additions to existing prognostic models for DLBCL.